David Baker

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis

Effects of cladribine on intrathecal and peripheral B and plasma cells

Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study

Synaptic Loss in Multiple Sclerosis Spinal Cord

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses

Axonal loss in the multiple sclerosis spinal cord revisited

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis

<scp>GPR55</scp> ‐dependent stimulation of insulin secretion from isolated mouse and human islets of <scp>L</scp> angerhans

How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis

Brain Endothelial miR-146a Negatively Modulates T-Cell Adhesion through Repressing Multiple Targets to Inhibit NF-κB Activation

Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis

Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB ₁ cannabinoid receptor agonists